Brendan P Lucey1, Kwasi G Mawuenyega2, Bruce W Patterson3, Donald L Elbert4, Vitaliy Ovod2, Tom Kasten2, John C Morris5, Randall J Bateman5. 1. Department of Neurology, Washington University School of Medicine, St Louis, Missouri2Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, Missouri. 2. Department of Neurology, Washington University School of Medicine, St Louis, Missouri. 3. Department of Medicine, Washington University School of Medicine, St Louis, Missouri. 4. Department of Biomedical Engineering, Washington University, St Louis, Missouri. 5. Department of Neurology, Washington University School of Medicine, St Louis, Missouri2Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, Missouri5Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, Missouri.
Abstract
Importance: Recent studies found that the concentration of amyloid-β (Aβ) fluctuates with the sleep-wake cycle. Although the amplitude of this day/night pattern attenuates with age and amyloid deposition, to our knowledge, the association of Aβ kinetics (ie, production, turnover, and clearance) with this oscillation has not been studied. Objective: To determine the association between Aβ kinetics, age, amyloid levels, and the Aβ day/night pattern in humans. Design, Setting, and Participants: We measured Aβ concentrations and kinetics in 77 adults aged 60 to 87 years with and without amyloid deposition by a novel precise mass spectrometry method at the Washington University School of Medicine in St Louis, Missouri. We compared findings of 2 orthogonal methods, enzyme-linked immunosorbent assay and mass spectrometry, to validate the day/night patterns and determine more precise estimates of the cosinor parameters. In vivo labeling of central nervous system proteins with stable isotopically labeled leucine was performed, and kinetics of Aβ40 and Aβ42 were measured. Interventions: Serial cerebrospinal fluid collection via indwelling lumbar catheter over 36 to 48 hours before, during, and after in vivo labeling, with a 9-hour primed constant infusion of 13C6-leucine. Main Outcomes and Measures: The amplitude, linear increase, and other cosinor measures of each participant's serial cerebrospinal fluid Aβ concentrations and Aβ turnover rates. Results: Of the 77 participants studied, 46 (59.7%) were men, and the mean (range) age was 72.6 (60.4-87.7) years. Day/night patterns in Aβ concentrations were more sharply defined by the precise mass spectrometry method than by enzyme-linked immunosorbent assay (mean difference of SD of residuals: Aβ40, -7.42 pM; P < .001; Aβ42, -3.72 pM; P < .001). Amyloid deposition diminished day/night amplitude and linear increase of Aβ42 but not of Aβ40. Increased age diminished day/night amplitude of both Aβ40 and Aβ42. After controlling for amyloid deposition, amplitude of Aβ40 was positively associated with production rates (r = 0.42; P < .001), while the linear rise was associated with turnover rates (r = 0.28; P < .05). The amplitude and linear rise of Aβ42 were both associated with turnover (r = -0.38; P < .001) and production (r = 0.238; P < .05) rates. Conclusions and Relevance: Amyloid deposition is associated with premature loss of normal Aβ42 day/night patterns in older adults, suggesting the previously reported effects of age and amyloid on Aβ42 amplitude at least partially affect each other. Production and turnover rates suggest that day/night Aβ patterns are modulated by both production and clearance mechanisms active in sleep-wake cycles and that amyloid deposition may impair normal circadian patterns. These findings may be important for the designs of future secondary prevention trials for Alzheimer disease.
Importance: Recent studies found that the concentration of amyloid-β (Aβ) fluctuates with the sleep-wake cycle. Although the amplitude of this day/night pattern attenuates with age and amyloid deposition, to our knowledge, the association of Aβ kinetics (ie, production, turnover, and clearance) with this oscillation has not been studied. Objective: To determine the association between Aβ kinetics, age, amyloid levels, and the Aβ day/night pattern in humans. Design, Setting, and Participants: We measured Aβ concentrations and kinetics in 77 adults aged 60 to 87 years with and without amyloid deposition by a novel precise mass spectrometry method at the Washington University School of Medicine in St Louis, Missouri. We compared findings of 2 orthogonal methods, enzyme-linked immunosorbent assay and mass spectrometry, to validate the day/night patterns and determine more precise estimates of the cosinor parameters. In vivo labeling of central nervous system proteins with stable isotopically labeled leucine was performed, and kinetics of Aβ40 and Aβ42 were measured. Interventions: Serial cerebrospinal fluid collection via indwelling lumbar catheter over 36 to 48 hours before, during, and after in vivo labeling, with a 9-hour primed constant infusion of 13C6-leucine. Main Outcomes and Measures: The amplitude, linear increase, and other cosinor measures of each participant's serial cerebrospinal fluid Aβ concentrations and Aβ turnover rates. Results: Of the 77 participants studied, 46 (59.7%) were men, and the mean (range) age was 72.6 (60.4-87.7) years. Day/night patterns in Aβ concentrations were more sharply defined by the precise mass spectrometry method than by enzyme-linked immunosorbent assay (mean difference of SD of residuals: Aβ40, -7.42 pM; P < .001; Aβ42, -3.72 pM; P < .001). Amyloid deposition diminished day/night amplitude and linear increase of Aβ42 but not of Aβ40. Increased age diminished day/night amplitude of both Aβ40 and Aβ42. After controlling for amyloid deposition, amplitude of Aβ40 was positively associated with production rates (r = 0.42; P < .001), while the linear rise was associated with turnover rates (r = 0.28; P < .05). The amplitude and linear rise of Aβ42 were both associated with turnover (r = -0.38; P < .001) and production (r = 0.238; P < .05) rates. Conclusions and Relevance: Amyloid deposition is associated with premature loss of normal Aβ42 day/night patterns in older adults, suggesting the previously reported effects of age and amyloid on Aβ42 amplitude at least partially affect each other. Production and turnover rates suggest that day/night Aβ patterns are modulated by both production and clearance mechanisms active in sleep-wake cycles and that amyloid deposition may impair normal circadian patterns. These findings may be important for the designs of future secondary prevention trials for Alzheimer disease.
Authors: M A Mintun; G N Larossa; Y I Sheline; C S Dence; S Y Lee; R H Mach; W E Klunk; C A Mathis; S T DeKosky; J C Morris Journal: Neurology Date: 2006-08-08 Impact factor: 9.910
Authors: Randall J Bateman; Ling Y Munsell; John C Morris; Robert Swarm; Kevin E Yarasheski; David M Holtzman Journal: Nat Med Date: 2006-06-25 Impact factor: 53.440
Authors: Diane Slats; Jurgen A H R Claassen; Petra E Spies; George Borm; Kees T C Besse; William van Aalst; Jack Tseng; Magnus J C Sjögren; Marcel G M Olde Rikkert; Marcel M Verbeek Journal: Neurobiol Aging Date: 2011-08-31 Impact factor: 4.673
Authors: Jinhe Li; Daniel A Llano; Teresa Ellis; David LeBlond; Anahita Bhathena; Stanford S Jhee; Larry Ereshefsky; Robert Lenz; Jeffrey F Waring Journal: Alzheimers Dement Date: 2011-11-02 Impact factor: 21.566
Authors: Rachel Potter; Bruce W Patterson; Donald L Elbert; Vitaliy Ovod; Tom Kasten; Wendy Sigurdson; Kwasi Mawuenyega; Tyler Blazey; Alison Goate; Robert Chott; Kevin E Yarasheski; David M Holtzman; John C Morris; Tammie L S Benzinger; Randall J Bateman Journal: Sci Transl Med Date: 2013-06-12 Impact factor: 17.956
Authors: Brendan P Lucey; Celedon Gonzales; Ujjwas Das; Jinhe Li; Eric R Siemers; J Randall Slemmon; Randall J Bateman; Yafei Huang; Gerard B Fox; Jurgen A H R Claassen; Diane Slats; Marcel M Verbeek; Gary Tong; Holly Soares; Mary J Savage; Matthew Kennedy; Mark Forman; Magnus Sjögren; Richard Margolin; Xia Chen; Martin R Farlow; Robert A Dean; Jeffrey F Waring Journal: Alzheimers Res Ther Date: 2015-07-29 Impact factor: 6.982
Authors: Bianca Van Broeck; Maarten Timmers; Steven Ramael; Jennifer Bogert; Leslie M Shaw; Marc Mercken; John Slemmon; Luc Van Nueten; Sebastiaan Engelborghs; Johannes Rolf Streffer Journal: Alzheimers Res Ther Date: 2016-05-19 Impact factor: 6.982
Authors: Kristine A Wilckens; Dana L Tudorascu; Beth E Snitz; Julie C Price; Howard J Aizenstein; Oscar L Lopez; Kirk I Erickson; Brian J Lopresti; Charles M Laymon; Davneet Minhas; Chester A Mathis; Daniel J Buysse; William E Klunk; Ann D Cohen Journal: Neurobiol Aging Date: 2018-07-26 Impact factor: 4.673
Authors: Margaret S Blattner; Sunil K Panigrahi; Cristina D Toedebusch; Terry J Hicks; Jennifer S McLeland; Ian R Banks; Claire Schaibley; Vitaliy Ovod; Kwasi G Mawuenyega; Randall J Bateman; Sharon L Wardlaw; Brendan P Lucey Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472
Authors: Brendan P Lucey; Terry J Hicks; Jennifer S McLeland; Cristina D Toedebusch; Jill Boyd; Donald L Elbert; Bruce W Patterson; Jack Baty; John C Morris; Vitaliy Ovod; Kwasi G Mawuenyega; Randall J Bateman Journal: Ann Neurol Date: 2018-01 Impact factor: 10.422
Authors: Diego Z Carvalho; Erik K St Louis; David S Knopman; Bradley F Boeve; Val J Lowe; Rosebud O Roberts; Michelle M Mielke; Scott A Przybelski; Mary M Machulda; Ronald C Petersen; Clifford R Jack; Prashanthi Vemuri Journal: JAMA Neurol Date: 2018-06-01 Impact factor: 18.302